Alzheimer's Tau Platform: Regimen A - AADvac1

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Preclinical Alzheimer's DiseaseProdromal Alzheimer's DiseaseAlzheimer Disease
Interventions
DRUG

AADvac1

Subcutaneous injection of AADvac1

DRUG

Anti-amyloid Monoclonal Antibody (mAb)

Active comparator: intravenous infusion of an anti-amyloid mAb

All Listed Sponsors
collaborator

Axon Neuroscience SE

INDUSTRY

collaborator

University of California, San Francisco

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Alzheimer's Therapeutic Research Institute

OTHER

collaborator

Alzheimer's Clinical Trials Consortium

OTHER

collaborator

National Institute on Aging (NIA)

NIH

lead

Paul S. Aisen

OTHER

NCT07167966 - Alzheimer's Tau Platform: Regimen A - AADvac1 | Biotech Hunter | Biotech Hunter